MX2020007442A - Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion. - Google Patents

Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.

Info

Publication number
MX2020007442A
MX2020007442A MX2020007442A MX2020007442A MX2020007442A MX 2020007442 A MX2020007442 A MX 2020007442A MX 2020007442 A MX2020007442 A MX 2020007442A MX 2020007442 A MX2020007442 A MX 2020007442A MX 2020007442 A MX2020007442 A MX 2020007442A
Authority
MX
Mexico
Prior art keywords
verification
protocol
imaging agent
effect
minimizing toxicity
Prior art date
Application number
MX2020007442A
Other languages
English (en)
Spanish (es)
Inventor
Gary W Ashley
Daniel V Santi
Brian Hearn
Shaun Fontaine
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of MX2020007442A publication Critical patent/MX2020007442A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyethers (AREA)
MX2020007442A 2018-01-12 2019-01-11 Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion. MX2020007442A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862617095P 2018-01-12 2018-01-12
US201862674483P 2018-05-21 2018-05-21
US201862700147P 2018-07-18 2018-07-18
US201862711421P 2018-07-27 2018-07-27
US201862711423P 2018-07-27 2018-07-27
US201862716788P 2018-08-09 2018-08-09
US201862716796P 2018-08-09 2018-08-09
PCT/US2019/013306 WO2019140266A1 (en) 2018-01-12 2019-01-11 Protocol for minimizing toxicity of combination dosages and imaging agent for verification

Publications (1)

Publication Number Publication Date
MX2020007442A true MX2020007442A (es) 2020-09-14

Family

ID=67218383

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020007442A MX2020007442A (es) 2018-01-12 2019-01-11 Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
MX2020007306A MX2020007306A (es) 2018-01-12 2019-01-11 Tratamiento sinergico de cancer.
MX2023005786A MX2023005786A (es) 2018-01-12 2020-07-13 Tratamiento sinergico de cancer.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020007306A MX2020007306A (es) 2018-01-12 2019-01-11 Tratamiento sinergico de cancer.
MX2023005786A MX2023005786A (es) 2018-01-12 2020-07-13 Tratamiento sinergico de cancer.

Country Status (10)

Country Link
US (4) US11730836B2 (cg-RX-API-DMAC7.html)
EP (2) EP3737383A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021510702A (cg-RX-API-DMAC7.html)
KR (2) KR20200110377A (cg-RX-API-DMAC7.html)
CN (2) CN111587115A (cg-RX-API-DMAC7.html)
AU (2) AU2019206623A1 (cg-RX-API-DMAC7.html)
CA (2) CA3087628A1 (cg-RX-API-DMAC7.html)
MX (3) MX2020007442A (cg-RX-API-DMAC7.html)
RU (1) RU2020126774A (cg-RX-API-DMAC7.html)
WO (2) WO2019140271A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020219943A1 (en) 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
US12472261B2 (en) 2019-08-28 2025-11-18 Prolynx Llc Conjugated inhibitors of DNA damage response
CN119213060A (zh) * 2022-04-14 2024-12-27 国立研究开发法人量子科学技术研究开发机构 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒
US20260034120A1 (en) * 2022-08-04 2026-02-05 Prolynx Llc Treating cancer with long-acting topoisomerase i inhibitor
WO2024030998A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Methods of treating cancer with long-acting topoisomerase i inhibitor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319854B1 (en) 1997-01-08 2016-11-30 Sigma-Aldrich Co. LLC Bioconjugation Of Macromolecules
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003253890A1 (en) 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
CA2502870C (en) 2002-10-31 2011-07-26 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
EP2307032A4 (en) * 2008-05-22 2014-08-20 Univ Ramot NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
US20100098654A1 (en) 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
EP2366105A1 (en) 2008-11-18 2011-09-21 Baxter International Inc. Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
CA2780645C (en) * 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
TW201215412A (en) 2010-08-30 2012-04-16 Sun Pharma Advanced Res Co Ltd Stable pharmaceutical composition
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014MN01819A (cg-RX-API-DMAC7.html) 2012-03-05 2015-07-03 Univ Ramot
TWI486341B (zh) * 2012-05-18 2015-06-01 高雄醫學大學 抑制atr與fancd2激活之組成物與方法
WO2014194289A1 (en) * 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
CN106061483B (zh) * 2013-10-04 2021-01-08 普洛林克斯有限责任公司 Sn-38的缓释结合物
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
US20150343100A1 (en) * 2014-05-28 2015-12-03 Memorial Sloan Kettering Cancer Center Bimodal fluorophore-labeled liposomes and associated methods and systems
EP3180031A1 (en) * 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016028636A1 (en) 2014-08-16 2016-02-25 Memorial Sloan Kettering Cancer Center Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods
JP6378584B2 (ja) 2014-08-29 2018-08-22 キヤノン株式会社 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム
US10196412B2 (en) * 2014-12-24 2019-02-05 The Board Of Trustees Of The Leland Stanford Junior University Probe for imaging PARP-1 activity
PL3277681T3 (pl) 2015-04-02 2019-10-31 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
HK1250646A1 (zh) * 2015-04-07 2019-01-11 Memorial Sloan Kettering Cancer Center 纳米粒子免疫偶联物
US10973925B2 (en) * 2015-04-28 2021-04-13 University Of Central Florida Research Foundation Inc. Methods and compositions for theranostic nanoparticles
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US10821195B2 (en) 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
US11154538B2 (en) 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
RU2725292C2 (ru) 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
AU2017258415B2 (en) * 2016-04-29 2023-03-30 Cornell University Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
CN106084005B (zh) * 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
CN107050471A (zh) * 2016-12-27 2017-08-18 中国药科大学 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用

Also Published As

Publication number Publication date
AU2019208024A1 (en) 2020-08-13
MX2020007306A (es) 2020-09-25
KR20200109345A (ko) 2020-09-22
EP3737416A1 (en) 2020-11-18
CN111587126A (zh) 2020-08-25
JP2021510701A (ja) 2021-04-30
US20240082436A1 (en) 2024-03-14
CA3087628A1 (en) 2019-07-18
WO2019140266A1 (en) 2019-07-18
US20230321286A1 (en) 2023-10-12
RU2020126774A (ru) 2022-02-14
JP2024012442A (ja) 2024-01-30
JP7703001B2 (ja) 2025-07-04
WO2019140271A2 (en) 2019-07-18
RU2020126853A3 (cg-RX-API-DMAC7.html) 2022-02-14
JP2021510702A (ja) 2021-04-30
EP3737383A4 (en) 2021-12-15
EP3737383A2 (en) 2020-11-18
US20200360545A1 (en) 2020-11-19
WO2019140271A3 (en) 2019-08-22
MX2023005786A (es) 2023-05-29
KR20200110377A (ko) 2020-09-23
US20200397778A1 (en) 2020-12-24
US11730836B2 (en) 2023-08-22
RU2020126853A (ru) 2022-02-14
AU2019206623A1 (en) 2020-07-16
CA3087967A1 (en) 2019-07-18
EP3737416A4 (en) 2022-03-30
CN111587115A (zh) 2020-08-25

Similar Documents

Publication Publication Date Title
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
ZA201907225B (en) Treatment of her2 positive cancers
HRP20211177T1 (hr) Korteksolon 17alfa-valerat za uporabu u liječenju tumora
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX379513B (es) Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA202090497A1 (ru) Соединения и композиции для лечения гематологических нарушений
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX394425B (es) Terapia de combinación con bromodominio e inhibidor de proteína extra terminal.
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
CY1125126T1 (el) Θεραπεια συνδυασμου αναστολεα βρωμοεπικρατειας και επιπλεον-τερματικης πρωτεϊνης
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
MX2022001249A (es) Tratamiento de tumores evasivos inmunitarios.
RU2015152785A (ru) Лечение злокачественной опухоли налтрексоном
HK1251488A1 (zh) 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
RU2020102713A (ru) Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
WO2019147338A3 (en) Radiopharmaceuticals and methods of use thereof
CN111867629A (zh) 抗her2抗体-药物偶联物在治疗癌症中的用途
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
EP4706653A3 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers